Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) Completed Phase 4 Trials for Diphtheria / Acellular Pertussis / Tetanus Prevention

IndicationsStatusPurposePhase
CompletedPrevention4
clinicaltrials.gov IdentifierTitleDrugs
NCT00282295US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease
NCT00610168Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.
NCT01147900Evaluation of Boostrix™10 Years After Previous Booster Vaccination
NCT01294605Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)
NCT01362322Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents